Dark

XBIO
Xenetic Biosciences, Inc.
stock NASDAQ

At Close

Sep 16, 2026 3:59:32 PM EDT

2.18USD-48.829%(-2.09)1,486,005

1.90Bid 2.50Ask 0.60Spread

Pre-market

Sep 16, 2026 9:27:30 AM EDT

2.84USD-33.489%(-1.43)55,818

After-hours

Sep 16, 2026 4:52:30 PM EDT

2.15USD-1.602%(-0.03)6,544

OverviewHistoricalExchangesShortsNews

Dec 8, 2021

11:24AM EST 'We are expanding the potential of CAR T cell therapy through the development of our XCART technology platform...' -Tweet From Xenetic Biosciences Benzinga

Nov 12, 2021

08:11AM EST Xenetic Biosciences Q3 2021 Net Loss $(1.4)M Benzinga

Oct 15, 2021

04:39PM EDT Xenetic Biosciences Enters Into Amendment Number 1 To MSA With Pharmsynthez To, Among Other Things, Terminate All Work Orders Under MSA Benzinga

Sep 9, 2021

08:08AM EDT Xenetic Biosciences, Inc. Receives Notice Of Allowance For XCART Patent Benzinga

Aug 13, 2021

04:55PM EDT Xenetic Biosciences Files Preliminary Prospectus Related To Resale Of Up To 950K Shares Issued To Selling Stockholder Benzinga

08:09AM EDT Xenetic Biosciences Reports Q2 Net Loss Of $1.1M Benzinga

Aug 12, 2021

10:17AM EDT Mid-Morning Market Update: Markets Down; US Producer Prices Rise 1% In July Benzinga

Aug 11, 2021

11:46AM EDT Xebetuc Biosciences Tweets 'XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value #oncology indications.' Benzinga

Jul 26, 2021

12:10PM EDT Mid-Day Market Update: Crude Oil Down 1%; Xenetic Biosciences Shares Spike Higher Benzinga

10:23AM EDT Mid-Morning Market Update: Markets Mostly Lower; Lockheed Martin Posts Mixed Q2 Results Benzinga

07:05AM EDT Xenetic Biosciences Sells 4.63M Shares of Common Stock to an Institutional Investor at $2.70/Share, Issues Warrants With an Exercise Price of $3.30/Share Benzinga

Jul 23, 2021

11:03AM EDT Xenetic Biosciences, Inc. (XBIO) shares are zooming on Friday morning trade, continuing its uptrend from July 20. The investor sentiment has been bullish on the stock despite the lack of any company-specific news to influence the stock. RTTNews

Mar 29, 2021

10:28AM EDT Xenetic Biosciences shares were trading higher after the company announced that it received approval to commence its exploratory patient biopsy study in eastern Europe to evaluate XCART. Benzinga

08:08AM EDT Xenetic Biosciences Reports Received Approval To Commence Exploratory Patient Biopsy Study In Eastern Europe Evaluating XCART Benzinga

Mar 17, 2021

08:07AM EDT Xenetic Biosciences FY20 Net Loss $(10.9M); Ended Year With $11.5M In Cash Benzinga

Mar 1, 2021

09:49AM EST A Look Into Healthcare Sector Value Stocks Benzinga

Feb 16, 2021

07:36AM EST Xenetic Biosciences, Inc. Announces Partner's Filing Of Registration Dossier In Russia For Epolong Product Candidate That Utilizes Xenetic's PolyXen Platform Technology Benzinga

Feb 1, 2021

09:47AM EST 5 Value Stocks In The Healthcare Sector Benzinga

Jan 11, 2021

08:36AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:23AM EST HC Wainwright & Co. Maintains Buy on Xenetic Biosciences, Raises Price Target to $5 Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

05:44AM EST Xenetic Bioscienced Announced ~2.45M Shares Registered Direct Offering Priced at $2.45/Share Benzinga

Dec 9, 2020

10:16AM EST Shares of biopharmaceutical company Xenetic Biosciences, Inc. (XBIO) are surging more than 275% Wednesday morning following positive data reported by its partner PJSC Pharmsynthez from the late stage study of Epolong, that uses Xenetic's PolyXen platform technology. RTTNews

08:44AM EST UPDATE: Xenetic Highlights PJSC Reported 'study enrolled approximately 150 patients with CKD across 36 medical institutions. The results of the study indicated that Epolong was non-inferior to Aranesp with respect to primary and secondary endpoints' Benzinga

08:43AM EST UPDATE: Xenetic Reports Partner, PJSC Pharmsynthez, Issued Data From Phase 3 Trial Of PolyXen To Develop Treatment For Anemia In Patients With Chronic Kidney Disease; PolyXen Platform Used To Develop Epolong, Which Helps Kidneys Promote Cell Production Benzinga

08:37AM EST Xenetic Biosciences Announces Positive Data From Partner's Pivotal Phase 3 Clinical Trial Utilizing PolyXen Platform Technology Benzinga

Nov 13, 2020

08:08AM EST Xenetic Biosciences Reports Net Loss Of ~$9.7M For Nine Months Ended Sept. 30 Benzinga

Oct 19, 2020

10:14AM EDT A Look Into Healthcare Sector Value Stocks Benzinga

Sep 8, 2020

09:34AM EDT Overview Of Value Stocks In The Healthcare Sector Benzinga

Aug 13, 2020

07:17AM EDT Xenetic Biosciences 1H Net Loss $2.1M Benzinga

Jul 28, 2020

10:54AM EDT Xenetic Biosciences Shares Quiet Following Co. Tweet 'We think we have a unique, differentiated platform that has real opportunity to make a clinical difference.' Benzinga